
ITOS Stock Forecast & Price Target
ITOS Analyst Ratings
Bulls say
ITeos Therapeutics Inc's current pipeline, featuring innovative product candidates such as EOS-850 and EOS-448, positions the company favorably within the biopharmaceutical sector, as these candidates target critical mechanisms in cancer treatment. The promising efficacy results from ongoing studies, particularly the reported 66% overall response rate in patients treated with the combination therapy of belantamab and dostarlimab, underscore the potential for improved clinical outcomes, which could enhance investor confidence. Moreover, the implementation of updated safety protocols in the Phase 3 studies may ultimately lead to reduced discontinuation rates and improved overall survival benefits, further strengthening the company’s growth outlook.
Bears say
ITeos Therapeutics Inc. reported no revenue in the fourth quarter of 2024, reflecting the company's ongoing challenges in generating income from its product candidates. The net loss of $1.01 per share was slightly better than the consensus estimate of a loss of $1.03 per share, but the lack of revenue raises concerns about the company's financial viability and ability to cover operating expenses. Additionally, the absence of revenue highlights significant risks related to the commercialization of its innovative therapies in a competitive biopharmaceutical landscape.
This aggregate rating is based on analysts' research of iTeos Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
ITOS Analyst Forecast & Price Prediction
Start investing in ITOS
Order type
Buy in
Order amount
Est. shares
0 shares